Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients

This is an observational study of pregnant persons in threatened labor. The study device will record electromyography signals, then the signals will be examined to determine who is in true labor and who is in threatened labor. The two goals are:

• To establish the thresholds for the Contraction Synchronization Index (CSI) and the False Labor Index (FSI) to be used by the Labor Status Monitor to diagnose in-Labor or Not-in-Labor for preterm patients with threatened labor
• To obtain feedback from subjects and providers to assist with enhancing patient comfort and provider training.

Study Overview

• Status: Recruiting
• Conditions: Preterm Birth; Threatened Preterm Labor; PreTerm Labor
• Intervention / Treatment: Device: Uterine electromyography

Detailed Description

This is a multicenter device optimization study, conducted as an observational cohort study.

All subjects will self-present for evaluation of threatened preterm labor. Threatened labor is defined here to mean that the diagnosis of in-Labor or Not-in-Labor is uncertain based on an initial evaluation. In practice, this means that the patient is experiencing uterine contractions, although her cervix is not dilated (opened) sufficiently for her to be immediately diagnosed as in-Labor and it is unclear if delivery will result from these contractions.

Current methods use legacy fetal monitoring devices to assist with making a working diagnosis of in-Labor or Not-in-Labor. Clinical management is then based on the working diagnosis. Legacy fetal monitoring devices are usually a tocodynamometer (Toco) and Doppler but alternately may be any FDA-cleared fetal monitor. There are several EMG-based FDA-cleared fetal monitors, although none are approved for use in preterm patients < 37 weeks.

With threatened labor, current methods typically require 2 to 4 hours to diagnose labor status (in-Labor or Not-in-Labor), although longer durations of evaluation are common. The Labor Status Monitor is designed to make a diagnosis using EMG within 1 to 2 hours, and with greater sensitivity and specificity than current methods. To establish the duration of recording needed to make a diagnosis with the Labor Status Monitor, EMG recording will be performed for at least 1 hour, and up to the time required to make the diagnosis using current methods.

The Labor Status Monitor uses electromyography (EMG) sensors that were specifically designed to record EMG from the pregnant uterus. These custom sensors are called "Area Sensors" since they report the EMG signal from a local area of the uterus. An array of 6 Area Sensors distributed widely across the front of the abdomen is used to depict the activity of the entire uterus.

The Labor Status Monitor is one of three devices under development by PreTeL - the other two are an EMG/ECG-based fetal monitor and the Uterine Stimulation Monitor. The three devices use the same placement of sensors and same methods of recording and storing data. The devices are differentiated by the methods of data analysis (e.g., the software analytics), which provide a different output for each indication. Each device uses the same array of six Area Sensors and requires at least two ECG sensors, one for reference and one for noise reduction. The EMG/ECG-based fetal monitor also reports the maternal and fetal heart rates, which requires an additional one or two ECG sensors to record the maternal and fetal ECG. The Labor Status Monitor and the Uterine Stimulation Monitor do not report maternal or fetal heart rate and hence are not required to use the additional two ECG sensors. However, we continue to place these additional sensors during our continuing development of the Labor Status Monitor because they provide additional uterine EMG data and quality control for the Area Sensors.

The purpose of this study is to obtain EMG data from subjects in threatened labor, then optimize the analytic software by establishing the parameter thresholds that are used to diagnose in-Labor or Not-in-Labor. To accomplish this goal, a gold standard diagnosis of True Labor or False Labor must be established for each subject. Gold standard diagnoses will be made retrospectively by waiting for the subject to deliver and assessing if the delivery resulted from the contractions that were occurring at the time of testing. To emphasize, the gold standard diagnoses (True Labor or False Labor) are made retrospectively and working diagnoses (in-Labor or Not-in-Labor) that are used for clinical management must be made prospectively. Establishing gold standard diagnoses also allows determination of the sensitivity and specificity of current methods in this population and will form the basis for evaluating the performance of the Labor Status Monitor.

This project is performed in two stages. In stage 1, training data is obtained, where the thresholds are set by the analysis team with knowledge of the gold standard diagnosis. In stage 2, validation data is obtained using the same procedures as stage 1, except the analysis team produces a diagnosis from the thresholds established in stage 1 and without knowledge of the gold standard diagnosis. Research information or results are not used for clinical management in either stage.

• Study Type: Observational
• Enrollment (Estimated): 181

Contacts and Locations

• Study Contact: Name: Roger C Young, MD; Phone Number: 603 359 8870; Email: ryoung@pretelhealth.com
• Study Contact Backup: Name: Marc Finch; Phone Number: 770 842 6806; Email: mfinch@pretelhealth.com

Study Locations

• United States
  • New York
    • Rochester, New York, United States, 14642
      • Recruiting
      • University of Rochester Medical Center
      • Contact: Neil Seligman, MD; Phone Number: 215-756-4897; Email: neil_seligman@urmc.rochester.edu
      • Contact: Ponnila Marinescu, MD; Phone Number: 2072292040; Email: ponnila_marinescu@urmc.rochester.edu
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Not yet recruiting
      • Dume University Medical Center
      • Contact: Danielle Lanpher; Email: danielle.lanpher@duke.edu
      • Contact: Jennifer Gilner; Phone Number: 919-201-2407; Email: jennifer.gilner@duke.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Low- or high-risk pregnancies that have achieved viability, anticipating a term delivery

Description

Inclusion Criteria:

Pregnant persons more than 24 and less than 37 weeks gestation experiencing threatened labor Singleton pregnancy

Exclusion Criteria:

Fetal anomaly that removes fetal well-being from consideration during labor Non-vertex presentation Fetal distress of other indications for emergent delivery

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preterm birth	BIrth prior to term	24 hours
Preterm birth	BIrth prior to term	48 hours
Preterm birth	BIrth prior to term	7 days
Preterm birth	BIrth prior to term	less than 37 weeks
Preterm birth	BIrth prior to term	Term

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survey of subjects and clinical personnel	Identify barriers to electrocardiography and electromyography recording	12 months

Collaborators and Investigators

• Sponsor: PreTeL, Inc
• Collaborators: Duke University; University of Rochester
• Investigators: Principal Investigator: Roger C Young, MD, PreTeL Chief Medical Officer

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2023
• Primary Completion (Estimated): August 28, 2024
• Study Completion (Estimated): October 28, 2024

Study Registration Dates

• First Submitted: November 27, 2023
• First Submitted That Met QC Criteria: November 27, 2023
• First Posted (Actual): December 5, 2023

Study Record Updates

• Last Update Posted (Actual): December 5, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pregnancy Complications; Obstetric Labor Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Premature Birth; Obstetric Labor, Premature
• Other Study ID Numbers: STUDY00007700

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Data shared will include summarized birth and EMG data of all participants. Individual birth outcomes will not be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No